الفهرس 
Introduction and Aim of the work
Tuberculosis: An overviewOnly 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
Tuberculosis is one of the oldest and most widespread life threatening infectious diseases that is still affecting human and animal population throughout the world. (162). This present study was conducted to:- Compare the outcome of FDC to ST in treatment of pulmonary and extra pulmonary TB in Assiut Governorate. This study was conducted inAssiut Chest Hospital Outpatient Clinic for TB,the joining inpatient and isolation department during the period from May 2015 to October 2016. In this prospective study, 120 patients with either pulmonary TB or extra pulmonary TB were enrolled.Eighty cases received the FDC regimen (40 pulmonary and 40 extra pulmonary) and 40 cases received the ST (20 pulmonary and 20 extra pulmonary), The study includednewlydiagnosed TB patients and thosepatientswho received TB treatment for less than one month .All Patients were above 18 years old at the time of enrolment. Each patient was clinically assessed and submitted to: plain x-ray chest postero-anterior and lateral view, sputum analysis for acid fast bacilli every 2 months, CBC, liver function test, kidney function test and uric acid.Follow up of investigations were done every 2 months with evaluation of any recorded side effects. As regard the demographic data, there was no significant difference between the patients received FDC and those received ST.The mean age for patients received FDCwas(36 ±10.7) years in the pulmonary group and (38±5.6) years in the extra pulmonary group and for patients received STwas (37±7.80) years in the pulmonary group and (34±3.3) years in the extra pulmonary group. About 60% of patients received FDC were males in the pulmonary group and 21% in the extra pulmonary. The percentage of the males with the pulmonary and extra pulmonary TB in the group of patients received ST are 65% and 55% respectively. As regard clinical improvement, both regimens show similar results includingfever, anorexia and sputum conversion with no statisticallysignificant difference(p<0.05) As regard liver function, there was statistically significant increase in the percentage of patients withincreased ALT, AST and bilirubin levels at follow up visits in both groups with (pvalue 0.000). At 2 months,there was statistically significant increase in the percentage of patients with increased AST levels in patient withST with (p value 0.000). At 4 months, there wasstatistically significant increase in the percentage of patients with increased ALT and AST levels inpatientsreceiving ST. Also, increase in the percentage of patients with increased levels of AST levels less than 2 fold in patients receiving STwith (p value 0.000). At 6 months, there was statistically significant increase in percentage of patients with the increased AST and ALT levels in patients with STwith (p value 0.000). As regard Bilirubin levels there was statistically significant increase in the percentage of patients with increased levels in patients receiving STat follow up visitswith (p value 0.000). As regards assessment of kidney function tests;there was statistically significant increase in the percentage of patients with increasedBUN,creatinine and uric acid at follow up visits in patients receiving FDC and STwith (p value 0.000). At 2, 4 and 6 months,there was statistically significant increase in the percentage of patients with normalBUN,creatinine and uric acid in patients receiving FDC .While increase in the percentage of patients with higher BUN,creatinine and uric acid levels in patients receiving STwith p value (0.000).While no statistically significant difference in the BUN levels at 6 months (p<0.05). As regard hematological changes, there was statistically significant increase in the percentage of patients with normal levels of WBCS, HB and PLT at follow up visitsin patients receiving FDC and STwith p value (0.000). At 2, 4 and 6 months, there was statistically significant increase in the percentage of patients with high WBCS, HB and PLT in patients with STwith p value (0.000). However none of the patients included in the current study needed to stop the medications.